Pathogenesis, Diagnostic Workup & "The Well Child"

Question	Answer
1. Define Immune Thrombocytopenia (ITP) in children.	ITP is an acquired immune-mediated hematologic disorder characterized by isolated thrombocytopenia (peripheral platelet count $<100,000/\mu\text{L}$) in the absence of other cytopenias or systemic disorders. - Chronological Stages (International Consensus): - Newly Diagnosed ITP: Within 3 months from diagnosis ($>75-80\%$ resolve spontaneously). - Persistent ITP: Thrombocytopenia lasting between 3 to 12 months. - Chronic ITP: Thrombocytopenia persisting $>12\text{ months}$.
2. Explain the immunopathogenesis of ITP.	1) Humoral Immunity: An antecedent viral infection triggers molecular mimicry, stimulating B-cells to produce IgG autoantibodies directed against platelet membrane glycoproteins, predominantly GPIIb/IIIa and GPIb/IX complexes. 2) Reticuloendothelial Destruction: Antibody-coated platelets are recognized by Fc-gamma ($Fc\gamma$) receptors on splenic macrophages and undergo rapid phagocytic destruction in the spleen. 3) Impaired Thrombopoiesis: Anti-platelet autoantibodies and cytotoxic T-cells also bind to and destroy bone marrow megakaryocytes, impairing platelet production.
3. What is the quintessential physical finding that rules AGAINST typical ITP?	SPLENOMEGALY. In typical acute childhood ITP, the spleen is NOT PALPABLE (or at most tip palpable in $<5\%$, representing normal pediatric splenic edge). VIVA TRAP: A significantly enlarged or firm spleen STRONGLY CONTRADICTS a simple diagnosis of ITP and mandates immediate Bone Marrow Aspiration to evaluate for Acute Leukemia, Lymphoma, Gaucher disease, or Portal Hypertension!
4. Is Bone Marrow Aspiration required to diagnose typical childhood ITP?	NO! Bone marrow aspiration is NOT recommended by ASH (American Society of Hematology) 2019 and IAP guidelines for children presenting with typical acute ITP (isolated thrombocytopenia, normal Hb and WBC count, normal peripheral smear, and absence of systemic signs). Absolute Indications for Bone Marrow Aspiration in Suspected ITP: 1) Presence of systemic "red flags": persistent fever, bone pain, limping, hepatosplenomegaly, or generalized lymphadenopathy. 2) Abnormalities on CBC other than thrombocytopenia: unexplained anemia, macrocytosis, neutropenia, or abnormal leukocytes. 3) Presence of blast cells, dysplastic cells, or teardrop cells on peripheral blood smear. 4) Before initiating systemic corticosteroids IF the clinician has any concern for occult Acute Lymphoblastic Leukemia (corticosteroid monotherapy will induce partial leukemic remission and tumor lysis syndrome, complicating subsequent diagnostic staging). 5) Failure to respond to first-line therapies (steroids/IVIG). 6) Prior to performing a splenectomy.
5. What are large platelets (megathrombocytes) on peripheral blood smear, and what do they signify?	Megathrombocytes are young, newly released platelets measuring $>3-4\,\mu\text{m}$ in diameter (often approaching the size of erythrocytes). - They signify accelerated compensatory bone marrow thrombopoiesis in response to acute peripheral platelet destruction, a key morphological hallmark of ITP.

Management Protocols (ASH 2019 / IAP Guidelines)

Question	Answer
6. What is the fundamental modern principle of managing childhood ITP?	"Treat the bleeding child, NOT the platelet number!" - Historically, treatment was initiated whenever the platelet count dropped $<20,000/\mu\text{L}$. - Modern guidelines (ASH 2019 / IAP) dictate that management is based on the severity of bleeding manifestations (Buchanan Bleeding Score) rather than the absolute platelet count. - Over $75-80\%$ of children with acute ITP achieve spontaneous complete recovery within 3 to 6 months without long-term sequelae.
7. Describe the "Watchful Waiting" (Observation Alone) approach in ITP.	- Indications: Recommended for children with Mild Cutaneous Bleeding only (petechiae and ecchymoses, Buchanan Bleeding Score Grade 1 or 2), regardless of whether the platelet count is $<10,000/\mu\text{L}$ or $>20,000/\mu\text{L}$, provided the child is active, has no mucosal bleeding, and reliable parental observation is assured. - Measures: Avoidance of contact sports, prohibition of antiplatelet drugs (Aspirin/NSAIDs), avoidance of IM injections, and counseling parents to report immediately if "wet purpura" (epistaxis, oral blood blisters) develops.
8. Detail the First-Line Pharmacotherapy options for childhood ITP with active mucosal bleeding (Wet Purpura).	1) Oral Corticosteroids (First-Line & Cost-Effective): - Short-Course Prednisolone: Oral $4.0\text{ mg/kg/day}$ for 3 to 4 days, OR $1.0-2.0\text{ mg/kg/day}$ for 7 to 14 days, followed by rapid discontinuation. - Rationale: Blocks macrophage $Fc\gamma$-receptors, decreases antibody production, and improves capillary endothelial stability. 2) Intravenous Immunoglobulin (IVIG): - Dose: $0.8-1.0\text{ g/kg}$ as a single intravenous dose over 4–6 hours (or $0.4\text{ g/kg/day}$ for 2-3 days). - Indicated when a rapid platelet rise is mandatory (severe mucosal hemorrhage, impending surgery, or head trauma). Platelets rise $>50,000/\mu\text{L}$ within 24–48 hours in $>80\%$ of children. 3) Intravenous Anti-D Immunoglobulin: - Dose: $50-75\text{ mcg/kg}$ IV single dose. Strictly restricted to Rh(D)-positive, direct Coombs-negative, non-splenectomized children. (Binds RBC Rh antigens; antibody-coated RBCs competitively block splenic macrophage Fc receptors).
9. What is the Emergency Protocol for Life-Threatening Intracranial Hemorrhage (ICH) in ITP?	Intracranial hemorrhage occurs in $<0.5\%$ of childhood ITP, but carries a $>50\%$ mortality. Triple Emergency Protocol: 1) Immediate High-Dose Platelet Transfusions: Give random donor or single-donor apheresis platelets immediately in large doses (double standard dose) or continuous infusion to provide immediate hemostatic plug formation despite ongoing destruction. 2) Intravenous Immunoglobulin (IVIG): $1.0\text{ g/kg}$ IV stat. 3) Intravenous Methylprednisolone: $30\text{ mg/kg}$ (max 1000 mg) pulse infusion over 30 minutes. 4) Neurosurgical Consultation: Immediate decompression if intracranial mass effect. 5) Recombinant Activated Factor VII (rFVIIa) as salvage therapy.
10. What are the second-line therapeutic options for Chronic or Refractory ITP?	1) Thrombopoietin Receptor Agonists (TPO-RAs): Eltrombopag (oral once daily) or Romiplostim (subcutaneous weekly). Stimulate megakaryocyte proliferation; high efficacy in chronic ITP. 2) Rituximab (Anti-CD20 Monoclonal Antibody): $375\text{ mg/m}^2$ weekly $\times 4$ doses; depletes autoantibody-producing B cells. 3) Splenectomy: Reserved strictly as a last resort for chronic ITP $>12\text{ months}$ with persistent severe, life-threatening bleeding refractory to medical therapies (deferred until $>5$ years of age).